VP16-213 (Etoposide)

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00254526PMID 7044594
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia.

  2009cited by this paper
• [Development of new substances in oncology. Many problems and some answers].

  2008cited by this paper
• Epipodophyllotoxin (VP16-213) in small cell carcinoma of the bronchus resistant to initial combination chemotherapy

  2004cited by this paper
• Podophyllotoxin derivative VP 16-213

  2004cited by this paper
• Pharmacokinetics of VP16-213 given by different administration methods

  2004cited by this paper
• Phase II study of VP16-213 (Etoposide) in refractory metastatic breast carcinoma

  2004cited by this paper
• Treatment of small cell carcinoma of the lung.

  1984cited by this paper
• VP-16-213: A phase II study of non-small cell lung cancer (NSCLC)

  1981cited by this paper
• Phase II study of oral VP-16-213 in hepatocellular carcinoma.

  1981cited by this paper
• Randomisierte Phase-II-Studie mit VP-16–213 (Etoposide®) in der Behandlung vom fortgeschrittenen Mammakarzinom

  1981cited by this paper
• A phase II study of oral VP-16-213 in non-seminomatous testicular cancer.

  1981cited by this paper
• [Randomized phase II study with VP-16-213 (etoposide) in the treatment of advanced breast cancer].

  1981cited by this paper
• VP16-213 as a single agent in advanced testicular tumors.

  1980cited by this paper
• Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group B

  1980cited by this paper
• Etoposide (VP-16-213).

  1979cited by this paper
• Phase I trial of a new form of an oral administration of VP-16-213.

  1979cited by this paper
• Analysis and interpretation of response rates for anticancer drugs.

  1979cited by this paper
• The delta and epsilon errors in the assessment of cancer clinical trials.

  1979cited by this paper
• Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.

  1979cited by this paper
• VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.

  1978cited by this paper
• VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.

  1978cited by this paper
• Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.

  1978cited by this paper
• VM 26 and VP 16–213: A comparative analysis

  1977cited by this paper
• Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP‐16‐213 (NSC 141540, 4′‐demethylepipodophyllotoxin 9‐(4,6‐0‐ethylidene‐β‐D‐glucopyranoside)

  1977cited by this paper
• [Therapeutic results using VP 16-213 alone or in combination with 5-fluorouracil in liver cancer (hepatoma)].

  1977cited by this paper
• VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.

  1976cited by this paper
• Comparison of the biologic activity of VP-16-213 given iv and orally in capsules or drink ampules.

  1976cited by this paper
• PHASE I clinical trial of an oral solution of VP-16-213.

  1976cited by this paper
• VP 16-213 in acute myelogenous leukaemia

  1976cited by this paper
• A clinical trial of the oral form of 4'-demethyl-epipodophyllotoxin-beta-D ethylidene glucoside (NSC 141540) VP 16-213.

  1975cited by this paper
• [Initial results with a epipodophyllotoxin derivative VP 16-213 in the treatment of acute leukemia].

  1975cited by this paper
• Clinical study of the new podophyllotoxin derivative, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-D-glucopyranoside) (NSC-141540; VP-16-213), in solid tumors.

  1975cited by this paper
• A clinical trial of the oral form of 4′‐demethyl‐epipodophyllotoxin‐β‐D ethylidene glucoside (NSC 141540) VP 16–213

  1975cited by this paper
• Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213).

  1974cited by this paper
• Epipodophyllotoxin VP 16213 in Treatment of Acute Leukaemia—Haematosarcoma and Solid Tumours

  1973cited by this paper
• Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).

  1972cited by this paper
• Clinical studies with podophyllum compounds SPI-77 (NSC-72274) and SPG-827 (NSC-42076).

  1966cited by this paper
• Clinical studies with podophyllum compounds SPI-77 (NSC-72274) and SPG-827 (NSC-42076).

  1966cited by this paper

• Plant-Derived Natural Products as Anticancer Agents

  2011cites this paper
• Akute myeloische Leukämien

  2006cites this paper
• The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation

  2004cites this paper
• The effect of dose on the bioavailability of oral etoposide

  2004cites this paper
• Schedule-dependent topoisomerase II-inhibiting drugs

  2004cites this paper
• Safety and efficacy of intraperitoneal injection of etoposide in oil suspension in mice with peritoneal carcinomatosis

  2004cites this paper
• Etoposide dosage and pharmacodynamics

  2004cites this paper
• Treatment of Acute Myeloid Leukemia in Children

  2003cites this paper
• Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide.

  2001cites this paper
• Optimizing antimetabolite‐based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia

  2000cites this paper
• A combination therapy with mitomycin c, etoposide, doxifluridine and medroxyprogesterone acetate as second line therapy for advanced breast cancer refractory to combination chemotherapy of cyclophosphamide, doxorubicin and 5 fluorouracil

  1997cites this paper
• Thiotepa and etoposide treatment of recurrent malignant gliomas: phase I study

  1997cites this paper
• Reproductive status in GTD treated with etoposide.

  1997cites this paper
• The clinical pharmacology of etoposide: an update.

  1996cites this paper
• [Full-term pregnancy in a patient diagnosed with acute leukemia treated with a protocol including VP-16].

  1993cites this paper
• A pilot study of EVAP/ABV chemotherapy in 25 newly diagnosed children with Hodgkin's disease.

  1993cites this paper
• Hypofibrinogenemia in a girl with Langerhans cell histiocytosis during etoposide and prednisolone therapy

  1993cites this paper
• Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer.

  1993cites this paper
• Treatment of the newly diagnosed adult with de novo acute myeloid leukemia.

  1993cites this paper
• Etoposide in the treatment of leukemias.

  1992cites this paper
• Targeting cancer chemotherapy using a monoclonal antibody (NCC‐LU‐243) conjugated with mitomycin C

  1992cites this paper
• Pharmacology of intrathecal VP-16-213 in dogs

  1992cites this paper
• 治療抵抗性白血病および再発白血病に対する経口エトポシド(VP-16)長期連日投与の寛解導入効果

  1991cites this paper
• The clinical pharmacology of etoposide

  1991cites this paper
• Mitoxantrone, etoposide, cisplatin and dexamethasone (MEPD) as salvage chemotherapy in resistant non-Hodgkin's lymphoma.

  1991cites this paper
• Clinical Pharmacology and Toxicity of Low Daily Administration of Oral Etoposide in Advanced Lung Cancer Patients

  1991cites this paper
• Etoposide in the management of leukemia: a review.

  1991cites this paper
• Etoposide in leukemia

  1991cites this paper
• Phase II trial of etoposide and cis-diaminodichloro-platinum in patients with refractory and relapsed Hodgkin's disease: Cancer and Leukemia Group B (CALGB) Study 8353.

  1990cites this paper
• Mitoxantrone and Constant Infusion Etoposide for Relapsed and Refractory Acute Myelocytic Leukemia

  1990cites this paper
• Treatment of refractory acute myeloid leukemia with mAMSA and VP 16‐213 in combination: Results of a clinical phase I/II study

  1989cites this paper
• 小児悪性腫瘍に対するVP-16 (Etoposide) 療法

  1989cites this paper
• Hypotension and cutaneous reactions associated with intravenous administration of etoposide in the dog.

  1988cites this paper
• Antibacterial Effect ofEtoposide InVitro

  1988cites this paper
• Ifosfamide: an old drug recently rediscovered.

  1988cites this paper
• Antibacterial effect of etoposide in vitro

  1988cites this paper
• The Clinical Pharmacology of Etoposide and Teniposide

  1987cites this paper
• In vitro chemoseparation of leukemic cells from murine bone marrow using VP16-213: importance of stem cell assays.

  1987cites this paper
• Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies

  1987cites this paper
• Comparison of CNS penetration, tissue distribution, and pharmacology of VP 16-213 by intracarotid and intravenous administration in dogs.

  1987cites this paper
• Phase II study of etoposide for carcinoma of the prostate.

  1986cites this paper
• Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.

  1986cites this paper
• Combination vincristine and VP-16-213: evaluation of drug sequence.

  1986cites this paper
• A phase I-II study of cytosine arabinoside, daunorubicin, and VP16-213 in adult patients with acute non-lymphocytic leukemia.

  1986cites this paper
• [Risk groups in acute, non-lymphatic leukemia in childhood. Analysis of the results of the cooperative therapeutic studies AML-BFM 78 and 83].

  1986cites this paper
• Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.

  1986cites this paper
• Clinical pharmacology of intracarotid etoposide

  1986cites this paper
• Laboratory chemosensitivity testing of human bladder carcinoma

  1985cites this paper
• High-performance liquid chromatography of etoposide in plasma and urine.

  1985cites this paper
• VP-16 in the treatment of malignant lymphomas: a report from the Swiss Group for Clinical Cancer Research (SAKK).

  1985cites this paper
• Treatment of acute myelogenous leukemia in children

  1985cites this paper
• Three months' treatment with cyclophosphamide, VP‐16‐213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer

  1985cites this paper
• In Vivo and in Vitro Pharmacologic Purification of Bone Marrow Contaminated with Tumor Cells Using VP16-213 and Nitrogen Mustard

  1984cites this paper
• Etoposide (VP-16-213) in malignant brain tumors: a phase II study.

  1984cites this paper
• New agents in non-small cell lung cancer.

  1984cites this paper
• Chemotherapy for advanced adenocarcinoma and squamous cell carcinoma of the lung with etoposide and cisplatin.

  1984cites this paper